SAN DIEGO & RALEIGH, N.C.--(BUSINESS WIRE)--SynteractHCR, a leading full-service global contract research organization (CRO), has recently moved to its expansive new facility in Carlsbad, California. The approximately 38,000 square feet of space at 5909 Sea Otter Place has been designed with an open concept to foster collaboration and creates a dynamic team environment, right in line with the company’s innovative business philosophy. Headquartered in San Diego County, with additional offices in the Research Triangle Park (RTP) area of North Carolina as well as 10 additional offices in Western, Central, and Eastern Europe, SynteractHCR sits in six of the top 10 biotech centers in the world and supports clients in conducting clinical trials worldwide.
SynteractHCR’s CEO Steve Powell says, “This move comes just one year after we doubled our space in Research Triangle Park and ensures we remain an important employer within the innovative local biotech and life science communities in San Diego, RTP and across the globe. The new Carlsbad space accommodates team members across all our core service offerings, and is an important focus of operations for our experienced, knowledgeable staff of clinical development professionals. We look forward to hosting project teams and clients in this invigorating new environment.”
SynteractHCR has seen some exciting changes in the recent months. Steve Powell joined SynteractHCR in July as CEO to further advance the CRO’s highly responsive service offerings for its innovative customers. Recently, CEO Powell and Vice President for Strategic Development Etienne Drouet were named to the 2017 PharmaVOICE 100, a list of the 100 most inspiring people in the life sciences industry, which annually identifies industry thought leaders and innovators that have the biggest impact on the field.
About SynteractHCR
With 800 staff members across 21 countries, SynteractHCR is an international full-service contract research organization with a successful three-decade track record supporting biotechnology, medical device and pharmaceutical companies in all phases of clinical development. SynteractHCR has conducted Phase I-IV studies on six continents and in more than 60 countries, offering broad therapeutic expertise, with notable depth in oncology, immunotherapy, CNS, and infectious disease, among other indications. With its “Shared Work – Shared Vision” philosophy, SynteractHCR provides customized services collaboratively and cost effectively, ensuring on-time delivery of quality data to help bring tomorrow’s treatments to patients.
